• $3.1B
    Market Cap
  • -24.33%
    1-Year Change
  • Medical Devices
    Industry

Key Performance

More
  • Earnings Score: 21
  • Momentum Score: 48
  • True Yield: N/A
  • Financial Health Score: 77
TradeSmith Loading

Latest Research & News

Integer to Participate in Truist Securities 2026 MedTech Conference on June 16

Integer Holdings Corporation (NYSE: ITGR), a leading medical device CDMO, announced its participation in the Truist Securities 2026 MedTech Conference on June 16, 2026. Executive leadership will participate in a fireside chat, with live webcast available on the company's investor relations website.

06/03/2026, 8:00 AM • GlobeNewswire

Why Integer Stock Leaped More Than 5% Higher Today

Integer Holdings (ITGR) surged over 5% after Oppenheimer analyst Suraj Kalia upgraded the stock to 'outperform' with a $115 price target. The upgrade was driven by Integer's announcement of a strategic review, suggesting potential acquisition interest from private equity firms. As a contract development and manufacturing organization (CDMO) for medical devices, Integer's modest valuations and profitable niche make it an attractive takeover target.

05/13/2026, 7:23 PM • The Motley Fool

Trends and Strategies in the 2026 Medical Device CMDO Market: Revenue to Exceed $354 Billion by 2033

The global medical device contract development and manufacturing organization (CDMO) market is expected to expand significantly at a CAGR of 13.12% from 2026 to 2033, driven by increased outsourcing by OEMs, demand for advanced connected devices, and the shift toward home care and minimally invasive treatments. CDMOs are becoming essential partners for managing regulatory complexities, reducing capital expenditure, and accelerating time-to-market.

04/28/2026, 10:56 AM • GlobeNewswire

Integer Announces Board Leadership Transition

Integer Holdings Corporation announced that independent Board Chair Pamela G. Bailey will not seek re-election at the May 20, 2026 Annual Meeting. Donald J. Spence, a director since 2016 and former CEO of Ebb Therapeutics and Lake Region Medical, will be appointed as the new independent Chair following the meeting.

04/06/2026, 5:00 PM • GlobeNewswire

Integer Stock Down 28% as Insider Reports Sale. Here's What to Know

Integer Holdings Corporation's stock has declined 28% over the past year. VP Corporate Controller Tom Thomas sold 825 shares worth $70,000 on March 13, 2026, representing 15.85% of his direct holdings. The article characterizes this as routine liquidity management rather than a loss of confidence. Despite revenue growth of 8% YoY to $1.85 billion in 2025, the company faces elevated leverage near 3.0x EBITDA, with investors focused on whether Integer can sustain margin expansion and balance sheet improvement.

03/24/2026, 4:20 PM • The Motley Fool

Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR); Molina Healthcare, Inc. (NYSE: MOH); and Soleno Therapeutics, Inc. (NASDAQ: SLNO): Grabar Law Office Investigates Claims on Your Behalf

Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Molina Healthcare for failing to disclose adverse medical cost trends; and Soleno Therapeutics for misrepresenting the safety profile of its drug candidate DCCR, which resulted in a patient death.

03/20/2026, 9:41 AM • GlobeNewswire

Important Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR): Soleno Therapeutics, Inc. (NASDAQ: SLNO); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Soleno Therapeutics for misrepresenting safety profile of drug candidate DCCR/VYKAT XR; and Unicycive Therapeutics for overstating FDA manufacturing compliance readiness. Shareholders who purchased shares during specified periods may be eligible to seek corporate reforms and compensation.

03/18/2026, 9:17 AM • GlobeNewswire

Integer Appoints James Flanagan and Aaron Kapito to Board of Directors

Integer Holdings Corporation announced the appointment of James Flanagan and Aaron Kapito to its Board of Directors as independent directors. Aaron Kapito's appointment is connected to a cooperation agreement with investment firm Irenic Capital Management. The moves are intended to enhance Integer's focus on growth and value creation, with the company expecting organic sales growth to return to market levels in 2026 and above-market growth in 2027.

03/12/2026, 8:00 AM • GlobeNewswire

Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Integer Holdings Corp. (NYSE: ITGR); Kyndryl Holdings (NYSE: KD); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Behalf

Grabar Law Office is investigating shareholder claims against four companies for alleged breaches of fiduciary duties and securities fraud. Corcept Therapeutics faces allegations of misrepresenting clinical trial data for its relacorilant drug, which received an FDA Complete Response Letter. Integer Holdings is accused of overstating its competitive position and concealing deteriorating sales. Kyndryl Holdings disclosed SEC investigations into cash management practices and internal control weaknesses. Molina Healthcare allegedly failed to disclose adverse medical cost trends and guidance risks.

03/03/2026, 2:47 PM • GlobeNewswire

Integer to Participate at Upcoming Investor Conferences

Integer Holdings Corporation announced that its executive leadership team will participate in three major investor conferences in March 2026: Raymond James 47th Annual Institutional Investors Conference (March 3), Oppenheimer 36th Annual Healthcare MedTech & Services Conference (March 17), and KeyBanc Capital Markets Healthcare Forum (March 18). Live webcasts and replays will be available on the company's investor relations website.

02/24/2026, 8:00 AM • GlobeNewswire

Surgery Partners Stock Down 39% as One Fund Slashes Stake by $19 Million

Irenic Capital Management sold 1,047,583 shares of Surgery Partners (SGRY) in Q4 2025, reducing its stake to just 0.09% of assets. The stock has declined 39.7% over the past year, underperforming the S&P 500 by 51.61 percentage points. While the company's operations remain solid with 6.6% revenue growth, concerns center on high leverage with net debt to EBITDA at 4.2x-4.6x in a higher rate environment.

02/23/2026, 3:03 PM • The Motley Fool

Irenic Dumps Most Papa John's Shares

Irenic Capital Management LP significantly reduced its Papa John's International position by approximately 70%, selling 748,592 shares in Q4 and retaining only 325,108 shares valued at $12.5 million. The stake now represents just 0.8% of the fund's AUM, dropping out of its top five holdings. Papa John's stock has underperformed the market, declining 30.7% over the past year while the S&P 500 gained 16.4%, amid struggling North American same-store sales.

02/22/2026, 10:08 AM • The Motley Fool

Why Integer Holdings Stock Flew Higher on Friday

Integer Holdings (ITGR) stock rose over 2% on Friday following strong Q4 2025 earnings results and multiple analyst upgrades. Benchmark upgraded the stock to buy with a $95 price target, while Wells Fargo and Truist Securities raised their price targets. The company reported 5% year-over-year sales growth to $472 million and a 22% increase in non-GAAP net income to $62 million.

02/20/2026, 7:23 PM • The Motley Fool

ITGR DEADLINE ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Integer Holdings Corporation Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - ITGR

A securities class action lawsuit has been filed against Integer Holdings Corporation for allegedly making materially false and misleading statements about its competitive position in the electrophysiology manufacturing market and overstating the growth potential of its EP devices. Investors who purchased Integer common stock between July 25, 2024 and October 22, 2025 may be entitled to compensation. The deadline to serve as lead plaintiff is February 9, 2026.

02/08/2026, 8:48 AM • GlobeNewswire

Integer Holdings Corporation (NYSE:ITGR) Accused of Securities Fraud after Stock Drops 32% -- Contact BFA Law before Monday February 9

A class action lawsuit has been filed against Integer Holdings Corporation (NYSE:ITGR) for securities fraud, alleging the company overstated demand for its electrophysiology devices while actual sales fell sharply. The stock dropped 32% on October 23, 2025, after Integer lowered its 2025 guidance and admitted to slower-than-forecasted adoption of two EP devices. Investors have until February 9, 2026, to join the lawsuit.

02/07/2026, 7:06 AM • GlobeNewswire

Peers

Statistics

More
Day Range
$89.76
$90.65
$90.10
1-Year Range
$63.32
$122.97
$90.10
Latest Close$90.10
Change
-$0.86 (-0.95%)
Volume262,473
Market Cap$3.1B
Shares Outstanding34.0M
P/E (TTM)22.67
Diluted EPS (TTM)$3.97
Enterprise Value$4.3B

Information as of 06/22/2026

Company Profile

INTEGER HOLDINGS CORP
https://www.integer.net
$3.1B
Market Cap
$141.8M
Net Income
Sector: Healthcare
Industry: Medical Devices
5830 Granite Parkway, Plano, TX, United States, 75024
214 618 5243

Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

Key Executives

  • Payman Khales
  • Andrew Senn
  • Diron Smith
  • John Harris
  • Kirk K. Thor

Current Ownership Distribution

  • Mutual Funds874.9M (55.68%)
  • Institutions694.9M (44.22%)
  • Insiders1.6M (0.10%)
  • Other0 (0.00%)